...
首页> 外文期刊>Environmental Health Perspectives >U.S. Food and Drug Administration Perspective of the Inclusion of Effects of Low-level Exposures in Safety and Risk Assessment
【24h】

U.S. Food and Drug Administration Perspective of the Inclusion of Effects of Low-level Exposures in Safety and Risk Assessment

机译:美国食品药品监督管理局将低水平接触的影响纳入安全性和风险评估的观点

获取原文
获取原文并翻译 | 示例
           

摘要

A brief overview is provided of some of the general safety and risk assessment procedures used by the different centers of the U.S. Food and Drug Administration (U.S. FDA) to evaluate low-level exposures. The U.S. FDA protects public health by regulating a wide variety of consumer products including foods, human and animal drugs, biologics, and medical devices under the federal Food, Drug, and Cosmetic Act. The diverse legal and regulatory standards in the act allow for the consideration of benefits for some products (e.g., drugs) but preclude them from others (e.g., food additives). When not precluded by statutory mandates (e.g., Delaney prohibition), the U.S. FDA considers both physiologic adaptive responses and beneficial effects.
机译:简要概述了美国食品药品监督管理局(U.S. FDA)不同中心用于评估低水平暴露的一些常规安全和风险评估程序。美国FDA通过根据联邦《食品,药品和化妆品法案》规范各种消费产品,包括食品,人类和动物药品,生物制品以及医疗器械,从而保护了公众健康。该法案中的各种法律和法规标准考虑了某些产品(例如药品)的利益,但又将其从其他产品(例如食品添加剂)中排除。如果不是法定命令(例如德莱尼禁令)排除的情况,美国FDA会同时考虑生理适应性反应和有益作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号